On May 22, 2025 Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, reported it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill (Press release, Exact Sciences, MAY 22, 2025, View Source [SID1234653300]). Presentations include new data on the Oncodetect molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score test, and the Cologuard test that underscore Exact Sciences’ expanding portfolio and commitment to advancing care through scientific excellence.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data Exact Sciences will present at ASCO (Free ASCO Whitepaper) 2025 reflect the scientific rigor and clinical significance of our expanding portfolio and pipeline," said Dr. Rick Baehner, MD, chief medical officer, Precision Oncology at Exact Sciences. "From MRD to MCED to CRC screening, we are advancing evidence-based innovations that help empower providers and deliver crucial answers to patients. Every study, partnership, and data point move us closer to a future where cancer is detected earlier and treated with greater precision."

Real-world evidence supporting the Cologuard test continues to grow, with ongoing research into repeat screening. New data from prominent experts and research groups reinforce the Oncotype DX test as a trusted, evidence-backed tool, further affirming its role as the standard of care for predicting chemotherapy benefit for breast cancer patients. Building on more than a decade of experience with Cologuard and 20 years of leadership with the Oncotype DX test, Exact Sciences continues to advance the future of precision oncology and multi-cancer screening.

New Data and Continuous Evidence Generation Underscore the Oncodetect Test’s Power to Detect Cancer Recurrence. Data from the Beta-CORRECT study further strengthens the clinical foundation of the Oncodetect test, confirming its role in helping guide treatment decisions and surveillance strategies for patients with stage II–IV colorectal cancer1. Expanding on this evidence to multiple solid tumor types, Exact Sciences and Flatiron Health continue enrollment in a multi-year, prospective study evaluating how MRD testing can improve cancer monitoring and treatment decisions in community care settings.

New Data Support Promise of MCED as Exact Sciences Prepares for LDT Launch. A modeling study found annual MCED testing could reduce late-stage cancer incidence by more than 40% and mortality by up to 18% in high-risk groups2. Additionally, the Falcon registry, a large, prospective real-world study of Exact Sciences’ MCED test, will track 25,000 participants against a 50,000-person standard-care cohort to assess adoption, outcomes, and patient experience. These findings come as Exact Sciences prepares to launch Cancerguard EX, its MCED lab-developed test (LDT), in the second half of the year, marking a significant step in expanding access to earlier cancer detection.

Exact Sciences abstracts at ASCO (Free ASCO Whitepaper) include:

Precision Oncology

The Association of Circulating Tumor DNA (ctDNA) with Recurrence in Patients with Stage II-IV Colorectal Cancer: The ꞵ-CORRECT Study
Saturday, May 31, 2025, from 9:00 AM to 12:00 PM CT
Abstract number: 3590
Molecular Residual Disease (MRD) in Solid Tumors
Monday, June 2, 2025, from 9:00 AM to 12:00 PM CT
Abstract number: TPS3186
Enhancing Recurrence Detection in Stage III Colorectal Cancer Patients Through Molecular Residual Disease Test-guided Surveillance: A Modeling Study
Abstract number: e15600
Patient outcomes in WSG-ADAPT according to NATALEE and MonarchE risk criteria
Monday, June 2, 2025, from 9:00 AM to 12:00 PM CT
Abstract number: 601
Screening

Adherence to repeat screening for colorectal cancer using the multi-target stool DNA test: Real-world analysis of patients from Federally Qualified Health Centers
Saturday, May 31, 2025, from 9:00 AM to 12:00 PM CT
Abstract number: 3630
A decade of progress: Trends in 5-year survival across 17 cancer types
Abstract number: e23262
The potential of multi-cancer early detection screening in reducing cancer incidence and mortality in high-risk groups: A modeling study
Saturday, May 31, 2025, from 1:30 PM to 5:30 PM CT
Abstract number: 10542
Falcon – Exact Sciences’ multi-cancer early detection (MCED) real-world evidence (RWE) registry
Saturday, May 31, 2025, from 1:30 PM to 5:30 PM CT
Abstract number: TPS11189
Evaluation of plasma methylated DNA markers for detection HPV-positive oropharyngeal squamous cell carcinoma: a case control study
Monday, June 2, 2025, from 9:00 AM to 12:00 PM CT
Abstract number: 6057
Feasibility of vaginal tampons versus vaginal swabs in the collection of vaginal fluid for endometrial cancer testing
Abstract number: e17617